No more LAGging behind PD-1: uncovering the unique role of LAG-3 in T-cell exhaustion

Yunju Jo,Hyung-seung Jin,Yoon Park

DOI: https://doi.org/10.1038/s41423-024-01227-w

2024-10-22

Cellular and Molecular Immunology

Abstract:Exhausted T (Tex) cells are a distinct subset of T cells that arise in response to prolonged antigen exposure during chronic infections or cancer. Although Tex cells exhibit reduced functionality, they still retain some protective abilities. Exhausted CD8+ T cells are a heterogeneous group consisting of four subsets: progenitor, intermediate, effector, and terminally exhausted. Each subset is characterized by distinct transcriptional, epigenetic, and functional traits [1]. Recent studies have indicated that the progenitor and intermediate Tex subsets are mainly responsible for the proliferative surge observed during anti-PD-1 immunotherapy, which results in the production of a large pool of functional effector cells, thereby sustaining the antitumor immune response [2]. However, blocking the PD-1 pathway alone typically fails to achieve lasting disease control in most patients. Simultaneous blockade of PD-1 and other immune checkpoint receptors can enhance CD8+ T-cell-mediated immunity, leading to more effective treatment outcomes. Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint receptor that is highly upregulated in exhausted T cells, hindering the development of protective immunity and making it a key target for cancer therapy. Relatlimab, a LAG-3-blocking antibody, was approved by the FDA in 2022 for use in combination with nivolumab, an anti-PD-1 antibody, to treat metastatic melanoma [3, 4]. Although the combination of relatlimab and nivolumab has shown clinical promise, it remains unclear whether this therapy synergistically rejuvenates exhausted T cells and what the underlying mechanisms of action might be.

immunology